99mTc-Labeled FAPI SPECT and 18F-FDG PET imaging for visualization and evaluation of connective tissue disease-associated interstitial lung disease Authors: Jingnan Wang, Xueyang Zhang, Yu Liu, Yangzhong Zhou, Guangjie Yang, Chao Fu, Xiang Li, Qian Wang, Fan Wang, Li Huo Published: 2025 ABSTRACT AbstractBackgroundThe pathogenesis of connective tissue disease-associated interstitial lung disease (CTD-ILD) involves complex interactions between inflammatory cell infiltration and fibroblast activation, which are pivotal in driving the disease progression. The aim of the study was to assess the feasibility of 99mTc-HFAPI imaging for visualizing active fibrotic process and 18F-FDG imaging for visualizing inflammatory process in CTD-ILD patients.ResultsA total of 54 CTD-ILD patients were enrolled. Visual analysis revealed that nearly half of the patients exhibited high tracer uptake on 99mTc-HFAPI imaging, whereas most patients showed low or moderate uptake on 18F-FDG imaging. 8 patients showed high uptake in both scans. 15 patients showed low or moderate 18F-FDG uptake but high 99mTc-HFAPI uptake. No patients demonstrated high 18F-FDG uptake coupled with low 99mTc-HFAPI uptake were observed among these 54 patients. Correlation analysis between 99mTc-HFAPI parameters and pulmonary function testing (PFT) results showed 99mTc-HFAPI uptake was significantly negatively correlated with forced vital capacity (FVC) [whole lung (wl) SUVmean: R=-0.45, p < 0.005; metabolic active volume (MAV): R=-0.41, p < 0.005; total lesion (TL): R=-0.45, p < 0.005] and diffusion capacity for carbon monoxide (DLCO) (wlSUVmean: R=-0.58, p < 0.005; MAV: R=-0.62, p < 0.005; TL: R=-0.65, p < 0.005). Significantly positive correlations were observed between 99mTc-HFAPI parameters and disease extent on HRCT (wlSUVmean: R = 0.51, p < 0.005; MAV: R = 0.53, p < 0.005; TL: R = 0.64, p < 0.005). In contrast, 18F-FDG parameters demonstrated weak or mild correlations with both PFT results and disease extent on HRCT.Conclusion99mTc-HFAPI imaging shows promising utility in assessing active fibrosis in CTD-ILD patients, demonstrating superior performance over 18F-FDG. The potential added value of dual-tracer imaging for characterization fibrotic and inflammatory processes might provide more insights of CTD-ILD.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13550-025-01340-5.Keywords: Interstitial lung disease, Connective tissue disease, 99mTc-HFAPI SPECT/CT, 18F-FDG PET/CT Background Interstitial lung diseases (ILD) encompass a heterogeneous group of parenchymal lung disorders with various etiologies, including autoimmune connective tissue diseases (CTD), drugs, radiation, environmental agents and idiopathic interstitial pneumonia [1]. ILD can present as a common and aggressive manifestation in patients with CTD, characterized by variable clinical courses and poor prognosis [2]. As CTD-ILD is the leading cause of morbidity and mortality in CTD patients, its clinical management is of great importance [3]. Diagnosis, early detection and risk stratification of ILD are typically based on symptoms, serological bio-markers, pulmonary function testing (PFT) and high-resolution CT (HRCT) [4, 5]. PFT provides a straightforward and rapid assessment of lung function and allows for repeated monitoring over time. Elevated serum level of Krebs von den lungen-6 (KL-6) has been detected in ILD patients and serves as a biomarker for screening and evaluating the severity of lung fibrosis. HRCT remains the standard imaging modality for assessing the extent and pattern of lung involvement [6]. However, as a morphological imaging technique, HRCT has limitations in distinguishing between inflammatory and fibrotic process. Despite the availability of multiple assessment tools, predicting disease progression in CTD-ILD remains challenging, underscoring the urgent need for improved diagnostic and management strategies [7]. Inflammatory responses within the pulmonary microenvironment promote fibroblast activation, driving progressive fibrosis and extracellular matrix remodeling. Therefore, novel imaging techniques capable of differentiating active inflammation from fibrosis could significantly enhance disease assessment and management. Positron emission tomography-computed tomography (PET/CT) using 18F-Fluorodeoxyglucose (18F-FDG), which targets the increased glucose metabolism characteristic of inflammatory cells, has been widely used to visualize inflammation. In contrast, fibroblast activation protein (FAP), overexpressed by activated fibroblasts, has emerged as a valuable target for imaging active fibrosis using FAP-specific inhibitors (FAPIs). Recent studies have confirmed the utility of FAPI tracers in various fibrotic conditions, including pulmonary fibrosis. Our previous research showed significant uptake of technetium-99m (99mTc)-labeled FAPI (99mTc-HFAPI) in lung lesions of idiopathic pulmonary fibrosis patients, with strong correlations to HRCT disease extent and PFT outcomes [8]. This study aims to assess the diagnostic utility of 99mTc-HFAPI imaging for assessing fibrotic activity in CTD-ILD patients and to explore the combined potential of combined 99mTc-HFAPI and 18F-FDG imaging for simultaneously visualizing active fibrotic and inflammatory processes. Materials and methods Patients This preliminary study consecutively enrolled 54 patients with a clinically established diagnosis CTD-ILD from the Department of Rheumatology and Clinical Immunology at our research center between June 2022, and April 2024. This study was approved by the institutional review board of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Ethics committee approval No. ZS-3038). All participants underwent 99mTc-HFAPI SPECT/CT and 18F-FDG PET/CT within an interval of less than five days. The diagnosis of connective tissue disease was established by two experienced rheumatologists with more than 20 years of specialized experience in this field according to the corresponding classification criteria. Interstitial lung disease was diagnosed according to American Thoracic Society/European Thoracic society guidelines based on clinical–radiologic features [9]. Additional key inclusion criteria were: the availability of HRCT, PFT and KL-6 within one week of the nuclear imaging, written informed consent, and age over 18 years old. Exclusion criteria were: non-CTD-associated pulmonary diseases such as lung cancer, lung surgery or radiotherapy, recent pulmonary infection at the time of study, and breastfeeding or pregnancy. Image procedures 18F-FDG PET/CT and HRCT imaging All patients fasted for at least 6 h and had their blood glucose levels checked before intravenous injection of 3.7 MBq (0.1 mCi)/kg of 18F-FDG. PET/CT scans were performed 50–60 min post-injection using a PoleStar m660 PET/CT scanner (SinoUnion Healthcare, Beijing, China). Non-contrast breath-hold HRCT of the chest region was conducted with a slice thickness of 1 mm, at 120 kV tube voltage and 200 mAs current. 99mTc-HFAPI scintigraphy and SPECT/CT imaging. The radiopharmaceutical 99mTc-HFAPI was prepared according to previously described method via the HFAPI kit by conjugating 99mTc-chelator moiety (6-hydrazinonicotinamide, HYNIC) with the FAP targeting moiety [8]. After injecting about 740 MBq 99mTc-HFAPI intravenously, image acquisition was performed using a dual-head Insight NM/CT Pro SPECT/CT scanner (Novel Medical, Beijing, China) equipped with a low-energy general-purpose collimator, 20% symmetric energy window, a peak at 140 keV photopeak of 99mTc. Whole-body anterior and posterior scintigraphy was acquired at 4 h after radiotracer injection with a 256 × 1024-pixel matrix at a scan speed of 20 cm/min. Then, a 99mTc-HFAPI SPECT/CT scan of the chest region was performed with a 128 × 128 matrix size, 60 projections and a 20 seconds’ exposure time per projection followed by a low-dose CT acquisition (for attenuation correction and anatomic localization). The SPECT data were normalized and corrected for attenuation, decay, and scatter by the manufacturer-supplied reconstruction technique using an iterative algorithm. Image analysis 18F-FDG PET/CT and 99mTc-HFAPI SPECT/CT imaging All PET and SPECT datasets were reviewed and analyzed by two nuclear medicine specialists, with any discrepancies resolved by consensus. The nuclear medicine specialists were blinded to patients’ clinical information and HRCT results. For visual analysis of 18F-FDG PET/CT, a three-grade visual score was determined by viewing the maximum intensity projection (MIP) images based on the FDG uptake: low (uptake slightly higher than the normal lung parenchyma), moderate (uptake lower or comparable to the mediastinal blood pool), and high (uptake above mediastinal blood pool). For semi-quantitative analysis of 18F-FDG PET/CT, tracer uptake in the pulmonary inflammatory regions was determined with maximum and mean standardized uptake values (FDG-SUVmax and FDG-SUVmean) and the metabolic active volume (FDG-MAV) in the regions of interest with isocontours set at 45% within the respective regions, by the automated lung segmentation protocol of a dedicated software package (MIM workstation, MIM Software, OH, USA). Total lesion FDG (FDG-TL) was calculated by multiplying the respective SUVmean and MAV. The 18F-FDG parameters of whole-lung (wl) FDG-SUVmax, SUVmean, MAV, TL were recorded. For visual analysis of 99mTc-HFAPI results, a three-grade visual score was determined by viewing the whole-body scintigraphy images: low (uptake lower or comparable to the liver), moderate (uptake slightly higher than the liver), and high (uptake markedly above the liver). For semi-quantitative analysis, using patient weight, injected activity, and 99mTc camera calibration factor, the SUVs in the respective regions of interest were calculated based on previous established quantitative reconstruction [10]. Tracer uptake in the pulmonary fibrotic regions was determined with FAPI-SUVmax and FAPI-SUVmean, FAPI-MAV and FAPI-TL by the same protocol of analyzing 18F-FDG PET/CT images. The 99mTc-HFAPI parameters of whole-lung FAPI-SUVmax, SUVmean, MAV, TL were recorded. HRCT imaging HRCT images were reviewed and scored by two senior radiologists masked to clinical information and nuclear medicine results. Differences in opinion were decided by consensus. HRCT pattern classification was assessed. Total disease extent, proportion of ground glass opacities (GGOs), reticular disease and honeycombing, and consolidations were measured semi-quantitatively to the nearest 5% at five levels in the axial orientation (1, origin of great vessels; 2, main carina; 3, pulmonary venous confluence; 4, halfway between the third and fifth section; 5, immediately above the right hemi-diaphragm) according to the visual staging system proposed by Goh et al. [11]. Statistical analysis All statistical analysis was performed with SPSS 22.0 and R (version 4.3.1). Quantitative data were expressed as mean ± standard deviation (SD) or median with interquartile range (IQR, P25-P75). Continuous variables between different groups were compared using a two-sided t-test. 95% confidence intervals for the difference were recorded. Correlations analyses were assessed using Spearman correlation test. For all tested, a P-value < 0.05 was considered statistically significant. Results Patients characteristics Fifty-four patients (34 males and 20 females, 52.41 ± 12.87 years of age) with CTD-ILD were enrolled in the study. The cohort included 31 cases of idiopathic inflammatory myopathies (IIM), 6 cases of systemic sclerosis (SSc), 5 cases of undifferentiated connective tissue disease (UCTD), 3 cases of primary Sjögren’s syndrome (pSS), 2 cases of rheumatoid arthritis (RA), 2 cases of systemic lupus erythematosus (SLE), 1 case of anti-neutrophil cytoplasmic antibody associated vasculitis (AAV), 1 case of mixed connective tissue disease (MCTD), 1 case of RA with IIM, 1 case of RA with SSc, and 1 case of SSc with SLE. The duration of CTD was 6.51 ± 4.80 years and the duration of ILD disease was 4.88 ± 3.73 years at the time of imaging. HRCT patterns were classified as nonspecific interstitial pneumonia (NSIP) in 30 cases, usual interstitial pneumonia (UIP) in 11 cases, organising pneumonia (OP) in 1 case, NSIP combined with OP in 6 cases, NSIP combined with UIP in 6 cases as well. All patients were receiving corticosteroids and/or disease-modifying anti-rheumatic drugs at baseline. and 21 patients were also receiving anti-fibrotic medication. Detailed demographic and clinical data of the study population are summarized in Table 1. Table 1Baseline demographic and clinical data of the study patientsPatient characteristicsN = 54Age (years ± SD)52.41 ± 12.87Sex (Male)20 (37.0%)Duration of CTD (years ± SD)6.51 ± 4.80Duration of ILD (years ± SD)4.88 ± 3.73CTD typesIIM31 (57.4%)SSc6 (11.1%)UCTD5 (9.3%)pSS3 (5.6%)RA2 (3.7%)SLE2 (3.7%)AAV1 (1.9%)MCTD1 (1.9%)RA + IIM1 (1.9%)RA + SSc1 (1.9%)SSc + SLE1 (1.9%)ILD typesNSIP30 (55.6%)UIP11 (20.4%)NSIP + OP6 (11.1%)NSIP + UIP6 (11.1%)OP1 (1.9%)Lab findings (median [IQR])CRP in mg/L2.72 [0.92, 7.08]ESR in mm/h13.00 [8.00, 26.75]KL-6 in U/mL1009.50 [629.50, 1389.25]Pulmonary function tests (mean ± SD)FVC (%)73.30 ± 17.33DLCO (%)52.98 ± 15.77Immunosuppressive/anti-fibrotic therapy (%)Corticosteroids53 (98.1%)Cyclophosphamide14 (25.9%)Tacrolimus14 (25.9%)Mycophenolate mofetil7 (13.0%)Methotrexate6 (11.1%)Tocilizumab5 (9.3%)Tofacitinib5 (9.3%)Cyclosporine A3 (5.6%)Azathioprine3 (5.6%)Anti-fibrotic therapy21 (39.6%)HRCT total disease extent (%) (mean ± SD)35.11 ± 16.10Visual score result99mTc-HFAPILow11 (20.4%)Moderate20 (37.0%)High23 (42.6%)18F-FDGLow26 (48.1%)Moderate20 (37.0%)High8 (14.8%)Definition of abbreviations: N, number; CTD, connective tissue disease; ILD, interstitial lung disease; IIM, idiopathic inflammatory myopathies; SSc, systemic sclerosis; UCTD, undifferentiated connective tissue disease; pSS, primary Sjögren’s syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; AAV, anti-neutrophil cytoplasmic antibody associated vasculitis; MCTD, mixed connective tissue disease; MSIP, nonspecific interstitial pneumonia; UIP, usual interstitial pneumonia; OP, organising pneumonia; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; KL-6, krebs von den lungen-6; FVC (% predicted), forced vital capacity; DLCO (% predicted), diffusion capacity of the lungs for carbon monoxide; HRCT, high resolution computed tomography Baseline demographic and clinical data of the study patients Definition of abbreviations: N, number; CTD, connective tissue disease; ILD, interstitial lung disease; IIM, idiopathic inflammatory myopathies; SSc, systemic sclerosis; UCTD, undifferentiated connective tissue disease; pSS, primary Sjögren’s syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; AAV, anti-neutrophil cytoplasmic antibody associated vasculitis; MCTD, mixed connective tissue disease; MSIP, nonspecific interstitial pneumonia; UIP, usual interstitial pneumonia; OP, organising pneumonia; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; KL-6, krebs von den lungen-6; FVC (% predicted), forced vital capacity; DLCO (% predicted), diffusion capacity of the lungs for carbon monoxide; HRCT, high resolution computed tomography Pulmonary tracer uptake For 99mTc-HFAPI, normal physiological uptake was observed primarily in the intestinal tract, gallbladder, liver, urinary bladder, kidneys and thyroid, with rapid clearance and no apparent retention in the blood circulation at late time point. No elevated pulmonary tracer uptake was observed in healthy lung regions, therefore any focal or diffuse increase in tracer uptake within the lungs was considered abnormal. Among the CTD-ILD patients, varying degrees of increased pulmonary tracer uptake were observed in affected lung regions. MAV was clearly delineated in the pulmonary parenchyma on both 99mTc-HFAPI SPECT/CT and 18F-FDG PET/CT imaging (Fig. 1). Based on visual analysis, 99mTc-HFAPI imaging revealed low uptake in 11 (20.4%) patients, moderate uptake in 20 (37.0%) patients and high uptake in 23 (42.6%) patients. In contrast, 18F-FDG imaging showed, low uptake in 26 (48.1%) patients, moderate uptake in 20 (37.0%) patients and high uptake in 8 (14.8%) patients. 8 patients exhibited high uptake on both scans. 15 patients showed low or moderate 18F-FDG uptake but high 99mTc-HFAPI uptake. No patients showed high 18F-FDG uptake with low 99mTc-HFAPI uptake. Figures 2, 3 and 4 illustrate examples of three patients with different imaging findings on 99mTc-HFAPI SPECT/CT, 18F-FDG PET/CT and HRCT. Given that patients with IIM constituted the majority (57.4%) of the cohort, 99mTc-FAPI uptake between IIM and other subtypes of CTD was compared. No significant differences were observed in FAPI uptake parameters, including wlSUVmax, wlSUVmean, MAV, and TL between IIM and other subtypes of CTD (wlSUVmax 4.34 ± 1.33 vs. 4.27 ± 1.35, p = 0.862; wlSUVmean 1.11 ± 0.38 vs. 1.13 ± 0.40, p = 0.740; MAV 296.13.21 ± 164.89 vs. 356.56 ± 212.59, p = 0.245; TL 724.70 ± 471.64 vs. 835.15 ± 549.80, p = 0.431). Additionally, FAPI uptake between different ILD patterns UIP and NSIP was also compared. A trend toward higher 99mTc-FAPI uptake was observed in UIP compared to NSIP, with MAV showing a statistically significant difference (wlSUVmax 4.20 ± 1.26 vs. 4.13 ± 1.32, p = 0.872; wlSUVmean 1.20 ± 0.48 vs. 1.06 ± 0.32, p = 0.377; MAV 432.49 ± 212.83 vs. 294.16 ± 167.50, p = 0.036; TL 975.11 ± 529.14 vs. 684.33 ± 418.44, p = 0.074). Representative images of 99mTc-HFAPI SPECT/CT and 18F-FDG PET/CT scans in a 38-year-old female patient diagnosed as rheumatoid arthritis (RA) and idiopathic inflammatory myopathies (IIM) related interstitial lung disease (ILD). The region of metabolic active volume could be delineated clearly by the automated lung segmentation protocol in both 99mTc-HFAPI SPECT/CT and 18F-FDG PET/CT imaging. The pink line enclosed region delineates the lung region and the blue line enclosed region delineates the metabolic active volume of the two tracers, respectively. 99mTc-HFAPI SPECT/CT maximum intensity projection (MIP) (A), transverse low-dose CT (B), transverse 99mTc-HFAPI SPECT (C), transverse SPECT/CT fusion (D), 18F-FDG PET/CT MIP (E), transverse low-dose CT (F), transverse 18F-FDG PET (G), transverse 18F-FDG PET/CT fusion (H) A 36-year-old male patient diagnosed as IIM-ILD. 99mTc-HFAPI whole-body scintigraphy anterior and posterior projection (A), 99mTc-HFAPI SPECT/CT MIP (B), transverse SPECT/CT fusion (C), transverse HRCT (D), 18F-FDG PET/CT MIP(E), transverse 18F-FDG PET/CT fusion (F). Intensely increased 99mTc-HFAPI uptake is observed, with the whole-lung (wl) SUVmax of 3.71, wlSUVmean of 0.81, metabolic active volume (MAV) of 392.53 cm3, total lesion (TL) of 940.32 cm3. Markedly increased 18F-FDG uptake is visualized as well, with the whole-lung (wl) SUVmax of 3.17, wlSUVmean of 0.70, metabolic active volume (MAV) of 183.07 cm3, total lesion (TL) of 349.94 cm3. Dominant reticulations and bronchiectasis and moderate extent of ground glass opacities (GGOs) are observed on HRCT images. The patient had decreased PFT (FVC 67%, DLCO 49%) A 54-year-old male patient diagnosed as IIM-ILD. 99mTc-HFAPI whole-body scintigraphy anterior and posterior projection (A), 99mTc-HFAPI SPECT/CT MIP (B), transverse SPECT/CT fusion (C), transverse HRCT (D), 18F-FDG PET/CT MIP (E), transverse 18F-FDG PET/CT fusion (F). There is slightly increased 99mTc-HFAPI (wlSUVmax of 2.55, wlSUVmean of 0.78, MAV of 211.08 cm3, TL of 284.95 cm3) and 18F-FDG (wlSUVmax of 2.28, wlSUVmean of 0.57, MAV of 106.85 cm3, TL 128.22 of cm3) uptake in the subpleural region corresponding to the areas of small linear opacities, lines and consolidations on HRCT images. The patient had normal PFT results A 69-year-old male patient diagnosed as IIM-ILD. Discrepancies were observed in the two tracers’ imaging results. 99mTc-HFAPI whole-body scintigraphy anterior and posterior projection (A), 99mTc-HFAPI SPECT/CT MIP (B), transverse SPECT/CT fusion (C), transverse HRCT (D), 18F-FDG PET/CT MIP(E), transverse 18F-FDG PET/CT fusion (F). There is severely increased 99mTc-HFAPI (wlSUVmax of 3.78, wlSUVmean of 1.13, MAV of 506.63cm3, TL of 1170.07cm3) uptake in the marked reticular pattern and mild to moderate bronchiectasis pattern on HRCT images. While only low 18F-FDG (wlSUVmax of 2.33, wlSUVmean of 0.60, MAV of 229.40 cm3, TL of 282.33cm3) uptake was observed. There is marked reticular pattern and GGOs with the presence of honeycombing on HRCT images. The patient had normal FVC (% predicted) and decreased DLCO (% predicted) (64%) Correlations between tracer uptake and PFTs and serum KL-6 We analyzed correlations between tracer uptake parameters and PFT results. The 99mTc-HFAPI uptake over the whole lung wlSUVmean, MAV and TL FAPI showed significant negative correlations with baseline forced vital capacity (FVC) (wlSUVmean: R=−0.45, p < 0.005; MAV: R=−0.41, p < 0.005; TL: R=−0.45, p < 0.005), while FAPI-wlSUVmax did not (R=−0.20, p = 0.14). Similarly, strong and significant negative correlations were found between 99mTc-HFAPI parameters the baseline and diffusion capacity for carbon monoxide (DLCO) (wlSUVmean: R=−0.58, p < 0.005; MAV: R=−0.62, p < 0.005; TL: R=−0.65, p < 0.005), despite the wlSUVmax did not (R=−0.21, p = 0.13) (Fig. 5A). The 18F-FDG parameters displayed weaker or moderate negative correlations with both FVC and DLCO (Fig. 5B). Furthermore, statistical analysis showed weak or mild correlations between the serum KL-6 and 99mTc-HFAPI parameters (wlSUVmax: R = 0.08, p = 0.64; wlSUVmean: R = 0.27, p < 0.05; MAV: R = 0.41, p < 0.05; TL: R = 0.40, p < 0.05). Linear correlation between 99mTc-HFAPI and 18F-FDG uptake with pulmonary function tests (PFTs) results at baseline (R for Spearman’s correlation coefficient rho). The 99mTc-HFAPI parameters showed strong negative correlations with forced vital capacity (FVC) (% predicted) while the 18F-FDG parameters showed weak correlations with FVC (% predicted) (A). In addition, the 99mTc-HFAPI parameters showed similarly strong negative correlations with diffusing capacity of the lungs for carbon monoxide (DLCO) (% predicted), while the 18F-FDG parameters showed moderate correlations with DLCO (% predicted) (B) Relationship between tracer uptake and HRCT morphological patterns All 99mTc-HFAPI parameters including wlSUVmax, wlSUVmean, MAV and TL showed significant positive correlations with total disease extent on HRCT imaging (wlSUVmax: R = 0.32, p < 0.005; wlSUVmean: R = 0.51, p < 0.005; MAV: R = 0.53, p < 0.005; TL: R = 0.64, p < 0.005), whereas 18F-FDG parameters displayed weak correlations (wlSUVmax: R = 0.01, p = 0.94; wlSUVmean: R = 0.34, p < 0.05; MAV: R = 0.28, p < 0.05; TL: R = 0.33, p < 0.05) (Fig. 6). Reticular pattern on HRCT imaging, reflecting fibrotic disease, showed significant positive correlations with 99mTc-HFAPI parameters (wlSUVmax: R = 0.31, p < 0.005; wlSUVmean: R = 0.51, p < 0.005; MAV: R = 0.40, p < 0.005; TL: R = 0.52, p < 0.005), while showed weaker correlations with 18F-FDG parameters (wlSUVmax: R = 0.10, p = 0.48; wlSUVmean: R = 0.35, p < 0.05; MAV: R = 0.27, p = 0.05; TL: R = 0.36, p < 0.05). For honeycombing, presenting advanced pulmonary fibrosis, no significant associations were found with 99mTc-HFAPI parameters (wlSUVmax: R=−0.05, p = 0.73; wlSUVmean: R = 0.13, p = 0.34; MAV: R = 0.28, p = 0.05; TL: R = 0.26, p = 0.06). Ground glass opacities (GGOs), indicative of inflammatory infiltration, showed similarly mild or moderate correlations with both tracers’ parameters (FAPI-wlSUVmax: R = 0.28, p < 0.05; wlSUVmean: R = 0.23, p = 0.10; MAV: R = 0.32, p < 0.05; TL: R = 0.43, p < 0.005; FDG-wlSUVmax: R = 0.07, p = 0.6; wlSUVmean: R = 0.35, p < 0.05; MAV: R = 0.38, p < 0.005; TL: R = 0.43, p < 0.005). No significant correlations were observed between wither tracer and the extent of consolidations. The relationship between 99mTc-HFAPI and 18F-FDG uptake with ILD HRCT morphologic features (R for Spearman’s correlation coefficient rho). 99mTc-FAPI (A) and 18F-FDG (B) parameters wlSUVmax, wlSUVmean, MAV, TL in relation to the semi-quantitative scores of the extent of total disease (%), extent of reticular disease (%), extent of ground glass opacities (%), and extent of honeycombing (%) Changes of tracer uptake in response to clinical treatment Eight patients underwent follow-up examinations. We analyzed changes in 99mTc-HFAPI and 18F-FDG uptake in response to clinical treatment and correlated the with changes in PFT after a treatment period of 6–12 months. One patient with disease progression despite glucocorticoids and anti-fibrotic treatment, showed increased uptake on both tracers (Fig. 7, patient 1). Another patient also had disease acceleration despite increasing the dosage of glucocorticoids and anti-fibrotic treatment; this patient showed increased 99mTc-HFAPI uptake but decreased 18F-FDG uptake (Fig. 7, patient 2). One patients showed a slight reduction in FAPI uptake on follow-up, which was associated with improvements in pulmonary function (Fig. 7, patient 3). The remaining 5 patients exhibited stable tracer uptake on follow-up, which corresponded stable FVC results (Fig. 7, representative in patient 4). (A) Changes in tracer uptake and PFT results over time in response to clinical treatment in four patients. Patient 1 was a 47-year-old female patient diagnosed as UCTD-ILD. This patient showed reduction of PFT during follow-up (baseline FVC 71%, DLCO 53%, 12-month follow-up FVC 68%, DLCO 39%) and increases in both tracers’ uptake (FAPI-wlSUVmean from 1.12 at baseline to 1.45 at follow-up, FAPI-MAV from 151.75 cm3 to 166.01 cm3, FAPI-TL from 606.96 cm3 to 813.18 cm3, and increases in FDG-wlSUVmean from 0.73 at baseline to 0.93 at follow-up, FDG-MAV from 145.46 cm3 to 188.52 cm3, FDG-TL from 265.84 cm3 to 322.07 cm3). Patient 2 was a 25-year-old female patient diagnosed as SSc-ILD. This patient showed reduction of PFT during follow-up (baseline FVC 62%, DLCO 51%, 12-month follow-up FVC 52%, DLCO 36%). Increased 99mTc-HFAPI uptake was observed (FAPI-wlSUVmean from 1.19 at baseline to 1.59 at follow-up, FAPI-MAV from 207.51 cm3 to 255.46 cm3, FAPI-TL from 590.77 cm3 to 762.04 cm3), while the reduction of 18F-FDG uptake was observed (FDG-wlSUVmean from 1.21 at baseline to 0.79 at follow-up, FDG-MAV from 85.44 cm3 to 76.37 cm3, FDG-TL from 232.26 cm3 to 150.55 cm3). Patient 3 had improvements in pulmonary function, which was associated with reductions in 99mTc-HFAPI uptake and constant 18F-FDG uptake. Patient 4 showed stable pulmonary function and constant tracer’s uptake. (B) Representative 99mTc-HFAPI SPECT/CT and 18F-FDG PET/CT images at baseline and follow-up from the corresponding patients Discussion In this preliminary observational study, we conducted dual-tracer imaging using 99mTc-HFAPI and 18F-FDG to visualize active fibrotic and inflammatory processes in patients with CTD-ILD. Our findings illustrated variable patterns and intensities of uptake for these two tracers, reflecting the distinct and potentially divergent fibrotic and inflammatory processes occurring in individual patients, underscoring the complexity of clinical decision-making in CTD-ILD. Notably, we observed robust correlations between 99mTc-HFAPI uptake intensity and both PFT outcomes and HRCT disease extent, whereas the correlations between 18F-FDG uptake and these clinical indicators were comparatively weaker. In the pathology of CTD-ILD, inflammatory reaction leads to a profibrotic environment, triggering cascades of fibrotic process characterized by fibroblast activation and fibrotic tissue remodeling in the pathophysiology of pulmonary fibrosis [12]. However, current routine modalities in CTD-ILD evaluation cannot non-invasively assess the states of inflammatory and fibrotic process. While the value of 18F-FDG PET/CT in the assessment of disease severity, therapy efficacy and prognosis in ILD patients has been widely studied [13, 14], this inflammatory tracer imaging is limited in depicting the compete profile of the disease. Studies have highlighted that the fibroblastic foci are the key histologic feature of active fibrotic progress and may predict clinical outcomes in ILD [15, 16]. FAP has emerged as a valuable target for imaging active fibrosis using FAPIs. FAPI signal detected by PET correlates with the abundance of FAP expression [17]. To date, the potential of FAPI PET tracers for evaluating disease activity and risk stratification in ILD patients has been investigated [18, 19]. In our study, we utilized 99mTc-labeled FAPI due to its cost-effectiveness and lower radiation dose. We found variable tracers’ uptake among these patients (Figs. 2, 3 and 4). The discrepancies indicate the heterogeneous fibrotic and inflammatory process occurring in individual patients. Bahtouee et al. [20] evaluated the efficacy of two modalities 68Ga-FAPI-46 PET/CT and 99mTc-MIBI scintigraphy in ILD patients and also found distinct molecular phenotype, implicating the course of disease might vary among individual patient. Visualization of this distinct process is of potential significance in the personal management of CTD-ILD. In the following quantitative analysis, 99mTc-HFAPI parameters correlated significantly with PFT results, aligning with prior studies that utilized FAPI PET tracers in ILD. Bergmann and Distler et al. [21] evaluated the value of 68Ga-FAPI-04 PET/CT in SSc-ILD. They found FAPI uptake correlates with baseline and changes in FVC and DLCO. Kastrati et al. [22] also reported strong negative correlations between 68Ga-DATA5m.SA.FAPi-PET uptake and PFT results. In particular, the relationship between FAPI uptake and the morphological changes on HRCT has been explored in previous studies, demonstrating that FAPI uptake correlates with the extent of disease on HRCT [21, 23, 24]. Our results showed pronounced correlations between 99mTc-HFAPI uptake and reticular pattern on HRCT, consistent with histological observations that FAP expression peaks in early fibrotic stages but diminishes in advanced fibrosis such as honeycombing [25]. We also found higher FAPI uptake in UIP patterns, which may be related to its predominantly characteristic fibrotic phenotype. For the GGOs, studies have found that the correlations between FAPI uptake and GGOs extent were moderate [21, 23, 24] and marked FAPI uptake could be observed in GGOs pattern in individual patient [20]. We observed a moderate yet significant correlation between 99mTc-HFAPI uptake and GGOs pattern. This moderate correlation and elevated 99mTc-HFAPI uptake in GGOs region suggests early fibrotic activation occurring concurrently or soon after initial inflammatory changes, despite GGOs pattern is typically associated with active inflammation [26]. Follow-up assessments demonstrated that tracer uptake changes over time could reflect clinical progression or response to treatment. Patients experiencing clinical deterioration exhibited increased 99mTc-HFAPI uptake, and in some cases, this was accompanied by discordant changes in 18F-FDG uptake. Such findings emphasize the non-linear progression of fibrosis and inflammation and the potential of dual-tracer imaging in evaluating the disease status and in the individual patient management. In summary, the utility of 99mTc-FAPI imaging offers a means to visualize the dynamic course of CTD-ILD. Our findings illustrated the feasibility of the dual-tracer imaging in evaluating the disease. In clinical practice, when balancing the anti-inflammatory and anti-fibrotic treatment for individual CTD-ILD patients, accurately determining the disease activity of inflammation or fibrosis is a critical factor. The dual-tracer 99mTc-HFAPI and 18F-FDG imaging method may provide a deeper understanding of the status of both inflammatory and fibrotic process within the affected lungs. Future studies with longitudinal follow-up are needed to determine whether dual-tracer imaging can indeed improve risk stratification or therapeutic monitoring. Despite promising results, our study has several limitations. The heterogeneous patient population, ongoing treatments and lack of respiratory gating could impact quantitative accuracy. The absence of histopathological validation through tissue biopsy further limits definitive conclusions. Moreover, as an observational study, the availability of follow-up imaging was based on real-world clinical practice rather than a standardized protocol, which may have introduced selection bias and long-term prognostic outcomes were not addressed. In addition, SPECT inherently has relatively limited spatial resolution compared to PET, which could lead to potential inaccuracies in quantitative results. Future studies should include tissue biopsies, standardized imaging protocols, respiratory gating, and longitudinal designs to validate and extend these findings. Conclusion Our study demonstrates 99mTc-HFAPI imaging holds significant promise as an imaging modality for evaluating fibrotic activity in CTD-ILD. While 99mTc-HFAPI showed superior performance compared to 18F-FDG in our preliminary results, the potential significance of the dual-tracer imaging modality for characterization inflammatory and fibrosis process has to be confirmed in further well-designed prospective research. Supplementary Information Supplementary Material 1. Acknowledgements We thank the patients and their families for participating in this study. Abbreviations Technetium-99 m 6-hydrazinonicotinamide fibroblast activation protein inhibitors 18F-Fluorodeoxyglucose Connective tissue disease-associated interstitial lung disease Pulmonary function testing Forced vital capacity Diffusion capacity of the lungs for carbon monoxide Positron emission tomography computed tomography Single photon emission computed tomography Standardized uptake values Metabolic active volume Total lesion Author contributions JW and XZ: Conceptualization; Data curation; Formal analysis; Methodology; Writing- original draft. YL: Conceptualization; Methodology; Data curation. YZ: Validation; Writing– review & editing. GY: Methodology; Writing–editing. CF: Conceptualization; Methodology. XL and QW: Conceptualization; Methodology; Supervision; Writing– review & editing. FW: Conceptualization; Data curation. LH: Conceptualization; Data curation; Formal analysis; Methodology; Validation; Supervision; Writing– review & editing. All authors read and approved the final manuscript Funding This work was supported by National Key R&D Program of China (Grant No. 2024YFC2419400); National Natural Science Foundation of China (Grant No. U24A20758); Beijing Natural Science Foundation (Grant No. L242062); National High Level Hospital Clinical Research Funding (Grant No. 2022-PUMCH-D-001, 2022-PUMCH-D-002, 2022-PUMCH-C-020, 2022-PUMCH-A-107). CAMS Innovation Fund for Medical Sciences (CIFMS) (2023-I2M-2-005, 2021-I2M-1-005). No other potential conflict of interest relevant to this article was reported. Declarations Ethics approval and consent to participate Ethical approval was obtained by the Institutional Review Board of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Ethics committee approval No. ZS-3038). Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Jingnan Wang and Xueyang Zhang contributed equally to this work. Contributor Information Xiang Li, Email: xiang.li@meduniwien.ac.at. Qian Wang, Email: wangqian_pumch@126.com. Li Huo, Email: huoli@pumch.cn. References Associated Data Supplementary Materials Supplementary Material 1.